Global and Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size, Status and Forecast 2021-2027

Global and Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size, Status and Forecast 2021-2027

  • QYResearch
  • November 2021
  • Medical Equipments
  • 96 pages

Report Description

Global Common Cancer-associated Antigens (CAAs) Vaccine Scope and Market Size
Common Cancer-associated Antigens (CAAs) Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Common Cancer-associated Antigens (CAAs) Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others

Segment by Application
Pediatrics
Adults

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies

Have query on this report?

Make an Enquiry
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tecemotide
List of Tables
Table 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tecemotide
Table 3. Key Players of Astuprotimut-R
Table 4. Key Players of Tertomotide
Table 5. Key Players of Nelipepimut-S

Success Stories

Our Clients